CroíValve Announces First Implant of a Novel Minimally Invasive Device for Tricuspid Regurgitation in US Early Feasibility Study October 24, 2024 Read More »
CroíValve Announces $16 Million Equity Financing to Fund US Early Feasibility Study of Novel Transcatheter Tricuspid Device August 7, 2024 Read More »
Positive Six-Month Results from CroíValve’s TANDEM I Study to Treat Tricuspid Regurgitation Presented at New York Valves 2024 June 10, 2024 Read More »
CroíValve is set to challenge as tricuspid regurgitation treatment space heats up April 25, 2024 Read More »
CroíValve Announces FDA IDE Approval and Initiation of its Early Feasibility Study January 25, 2024 Read More »
